1. The Wnt-dependent signaling pathways as target in oncology drug discovery

   • Nico Janssens
   • Michel Janicot
   • Tim Perera

   Preclinical Studies Open access 28 January 2006 Pages: 263 - 280

   

2. Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin^®) in CD1 mice following intravenous and intraperitoneal injection

   • Boswell GW
   • DR Miles
   • M Mesfin

   Preclinical Studies 09 March 2006 Pages: 281 - 289

3. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

   • Jing Li
   • Julie Brahmer
   • Sharyn D. Baker

   Preclinical Studies 17 February 2006 Pages: 291 - 297

4. A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance

   • Marc Salzberg
   • Miklos Pless
   • Richard Herrmann

   Phase I Studies 05 October 2005 Pages: 299 - 304

5. A phase I study of flavopiridol and docetaxel

   • Basil F. El-Rayes
   • Shirish Gadgeel
   • Philip A. Philip

   Phase I Studies 28 January 2006 Pages: 305 - 310

6. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

   • Werner Hilgers
   • Sandrine Faivre
   • Esteban Cvitkovic

   Phase I Studies 28 January 2006 Pages: 311 - 319

7. Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma

   • Thomas Olencki
   • Sareena Malhi
   • Ronald M. Bukowski

   Phase I Studies 28 January 2006 Pages: 321 - 326

8. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors

   • Thierry Delaunoit
   • Patrick A. Burch
   • Charles Erlichman

   Phase I Studies 17 February 2006 Pages: 327 - 333

9. Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study

   • Robert P. Whitehead
   • Sheryl McCoy
   • James L. Abbruzzese

   Phase II Studies 28 January 2006 Pages: 335 - 341

10. A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)

    • Tanios S. Bekaii-Saab
    • Amir Mortazavi
    • Eric H. Kraut

    Phase II Studies 28 January 2006 Pages: 343 - 346

11. SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

    • R. P. Wong
    • T. Baetz
    • E. Eisenhauer

    Phase II Studies 08 March 2006 Pages: 347 - 351

12. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

    • Jaffer A. Ajani
    • Yixing Jiang
    • Archie Bleyer

    Phase II Studies 05 April 2006 Pages: 353 - 357

13. Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy

    • Hitendra Patel
    • Ronald Stoller
    • Ramesh K. Ramanathan

    Phase II Studies 08 March 2006 Pages: 359 - 363